Literature DB >> 28194669

MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.

Feng-Ting Huang1, Juan-Fei Peng2, Wen-Jie Cheng3, Yan-Yan Zhuang2, Ling-Yun Wang2, Chu-Qiang Li2, Jian Tang4, Wen-Ying Chen2, Yuan-Hua Li2, Shi-Neng Zhang5.   

Abstract

BACKGROUND: Transforming growth factor (TGF)-β-activated kinase 1 (TAK1) is one of the major regulators of inflammation-induced cancer cell growth and progression. MiR-143 dysregulation is a common event in a variety of human diseases including pancreatic ductal adenocarcinoma (PDA). AIMS: To identify the interaction between TAK1 and miR-143 in PDA.
METHODS: Data mining of TAK1 expression in PDA patient gene profiling was conducted. QRT-PCR and western blot were performed to detect the expression of TAK1 in PDA tissues and cell lines. Ectopic miR-143 and TAK1 were introduced to PDA cells. Cell growth, apoptosis and migration were examined. Xenograft models were used to examine the function of TAK1 in vivo. Western blot and luciferase assay were carried out to investigate the direct target of miR-143.
RESULTS: PDA patient gene profiling data (GSE15471 and GSE16515) showed that TAK1 mRNA was aberrantly up-regulated in PDA tissues. TAK1 protein levels were overexpressed in PDA tissues and cell lines. Overexpression of TAK1 was strongly associated with positive lymph node metastasis. Inhibition of TAK1 suppressed cell growth, migration, and induced cell apoptosis in vitro and in vivo. Further studies demonstrated that TAK1 was a direct target gene of miR-143. MiR-143 also inhibited PDA cells proliferation and migration, induced apoptosis and G1/S arrest. Moreover, TAK1 depletion inactivated MAPK and NF-κB pathway, mimicking the function of miR-143.
CONCLUSIONS: The study highlights that miR-143 acts as a tumor suppressor in PDA through directly targeting TAK1, and their functional regulation may provide potential therapeutic strategies in clinics.

Entities:  

Keywords:  MAPK; MiR-143; NF-κB; Pancreatic ductal adenocarcinoma; TAK1

Mesh:

Substances:

Year:  2017        PMID: 28194669     DOI: 10.1007/s10620-017-4472-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  50 in total

1.  TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.

Authors:  Jae-Hyuck Shim; Changchun Xiao; Amber E Paschal; Shannon T Bailey; Ping Rao; Matthew S Hayden; Ki-Young Lee; Crystal Bussey; Michael Steckel; Nobuyuki Tanaka; Gen Yamada; Shizuo Akira; Kunihiro Matsumoto; Sankar Ghosh
Journal:  Genes Dev       Date:  2005-10-31       Impact factor: 11.361

2.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Authors:  Mark Bloomston; Wendy L Frankel; Fabio Petrocca; Stefano Volinia; Hansjuerg Alder; John P Hagan; Chang-Gong Liu; Darshna Bhatt; Cristian Taccioli; Carlo M Croce
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

3.  Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress.

Authors:  Ole Morten Seternes; Bjarne Johansen; Beate Hegge; Mona Johannessen; Stephen M Keyse; Ugo Moens
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

4.  Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Authors:  Jin-Hyeok Hwang; Johannes Voortman; Elisa Giovannetti; Seth M Steinberg; Leticia G Leon; Yong-Tae Kim; Niccola Funel; Joo Kyung Park; Min A Kim; Gyeong Hoon Kang; Sun-Whe Kim; Marco Del Chiaro; Godefridus J Peters; Giuseppe Giaccone
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

5.  linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.

Authors:  Wang He; Qingqing Cai; Fenyong Sun; Guangzheng Zhong; Pei Wang; Hongyan Liu; Junhua Luo; Hao Yu; Jian Huang; Tianxin Lin
Journal:  Biochim Biophys Acta       Date:  2013-05-18

6.  The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.

Authors:  Alessandro Sorrentino; Noopur Thakur; Susanne Grimsby; Anders Marcusson; Verena von Bulow; Norbert Schuster; Shouting Zhang; Carl-Henrik Heldin; Maréne Landström
Journal:  Nat Cell Biol       Date:  2008-08-31       Impact factor: 28.824

7.  Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells.

Authors:  Sung Il Kim; Joon Hyeok Kwak; Hee-Jun Na; Jin Kuk Kim; Yan Ding; Mary E Choi
Journal:  J Biol Chem       Date:  2009-06-25       Impact factor: 5.157

8.  miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.

Authors:  Hung Pham; C Ekaterina Rodriguez; Graham W Donald; Kathleen M Hertzer; Xiaoman S Jung; Hui-Hua Chang; Aune Moro; Howard A Reber; O Joe Hines; Guido Eibl
Journal:  Biochem Biophys Res Commun       Date:  2013-08-21       Impact factor: 3.575

9.  MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.

Authors:  Adam E Frampton; Leandro Castellano; Teresa Colombo; Elisa Giovannetti; Jonathan Krell; Jimmy Jacob; Loredana Pellegrino; Laura Roca-Alonso; Niccola Funel; Tamara M H Gall; Alexander De Giorgio; Filipa G Pinho; Valerio Fulci; David J Britton; Raida Ahmad; Nagy A Habib; R Charles Coombes; Victoria Harding; Thomas Knösel; Justin Stebbing; Long R Jiao
Journal:  Gastroenterology       Date:  2013-10-09       Impact factor: 22.682

10.  microRNA target predictions across seven Drosophila species and comparison to mammalian targets.

Authors:  Dominic Grün; Yi-Lu Wang; David Langenberger; Kristin C Gunsalus; Nikolaus Rajewsky
Journal:  PLoS Comput Biol       Date:  2005-06-24       Impact factor: 4.475

View more
  12 in total

1.  [Expressions of TAK1 and TAB1 in esophageal cancer and their correlation with prognosis].

Authors:  Sai Cao; Meirong Cheng; Sue Liu; Xiaole Duan; Mei Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

2.  TAK1 regulates endothelial cell necroptosis and tumor metastasis.

Authors:  Lida Yang; Sayali Joseph; Tianliang Sun; Julia Hoffmann; Sophia Thevissen; Stefan Offermanns; Boris Strilic
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

3.  MiR-143-3p suppresses the progression of ovarian cancer.

Authors:  Haijuan Shi; Huimin Shen; Juan Xu; Shanshan Zhao; Shuzhong Yao; Nan Jiang
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

Review 4.  TAK1 signaling is a potential therapeutic target for pathological angiogenesis.

Authors:  Linxin Zhu; Suraj Lama; Jiang-Hui Wang; Guei-Sheung Liu; Leilei Tu; Gregory J Dusting
Journal:  Angiogenesis       Date:  2021-05-10       Impact factor: 10.658

5.  The mechanism of miR-143 inducing apoptosis of liver carcinoma cells through regulation of the NF-κB pathway.

Authors:  Yi Zheng; Fan Yang; Ling Fu; Kang Liu
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

6.  MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1.

Authors:  Lei Chang; Dongya Zhang; Huirong Shi; Yangyang Bian; Ruixia Guo
Journal:  Oncotarget       Date:  2017-09-16

7.  lncRNA DGCR 5/miR‑27a‑3p/BNIP3 promotes cell apoptosis in pancreatic cancer by regulating the p38 MAPK pathway.

Authors:  Xianjie Li; Shanxue Zhou; Tianyi Fan; Xuefeng Feng
Journal:  Int J Mol Med       Date:  2020-06-04       Impact factor: 4.101

8.  Differential Targeting of c-Maf, Bach-1, and Elmo-1 by microRNA-143 and microRNA-365 Promotes the Intracellular Growth of Mycobacterium tuberculosis in Alternatively IL-4/IL-13 Activated Macrophages.

Authors:  Ousman Tamgue; Lorna Gcanga; Mumin Ozturk; Lauren Whitehead; Shandre Pillay; Raygaana Jacobs; Sugata Roy; Sebastian Schmeier; Malika Davids; Yulia A Medvedeva; Keertan Dheda; Harukazu Suzuki; Frank Brombacher; Reto Guler
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

Review 9.  MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer.

Authors:  Jin'en Wu; Juntao Ding; Jing Yang; Xiaola Guo; Yadong Zheng
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

10.  Resibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3.

Authors:  Lu Liu; Yang Liu; Xiaojia Liu; Na Zhang; Genxiang Mao; Qingxuan Zeng; Mingxiao Yin; Danqing Song; Hongbin Deng
Journal:  Cancer Sci       Date:  2018-09-23       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.